|
TCEAL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.88737914186277E-14 |
| Normal-vs-Stage2 |
4.26620000004707E-06 |
| Normal-vs-Stage3 |
5.4989346409684E-13 |
| Normal-vs-Stage4 |
1.62547753035369E-12 |
| Stage1-vs-Stage2 |
1.200580E-01 |
| Stage1-vs-Stage3 |
3.347400E-01 |
| Stage1-vs-Stage4 |
7.203700E-03 |
| Stage2-vs-Stage3 |
4.820000E-02 |
| Stage2-vs-Stage4 |
9.778300E-04 |
| Stage3-vs-Stage4 |
7.876200E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.21679999998126E-06 |
| Normal-vs-Asian |
6.94829971337185E-10 |
| Caucasian-vs-AfricanAmerican |
5.053800E-01 |
| Caucasian-vs-Asian |
4.931400E-01 |
| AfricanAmerican-vs-Asian |
8.728200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.06847905260111E-13 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
7.260600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74338321556888E-12 |
| Normal-vs-Age(41-60Yrs) |
1.75415237890775E-14 |
| Normal-vs-Age(61-80Yrs) |
1.34680044894253E-10 |
| Normal-vs-Age(81-100Yrs) |
2.805700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.530800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.718400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.935400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.078200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.384600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.257800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.080500E-03 |
| Classical-VS-Follicular |
2.376100E-02 |
| Classical-VS-Other |
9.861600E-01 |
| Classical-VS-Normal |
1.6242562850266E-12 |
| Tall-VS-Follicular |
7.71410000000028E-05 |
| Tall-VS-Other |
1.666010E-01 |
| Tall-VS-Normal |
1.56541446472147E-14 |
| Follicular-VS-Other |
4.684200E-01 |
| Follicular-VS-Normal |
1.87470000001522E-06 |
| Other-VS-Normal |
1.319480E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.15605352752391E-12 |
| Normal-vs-N1 |
9.99200722162641E-16 |
| N0-vs-N1 |
1.157640E-03 |
|
|
